AIRLINK 79.80 Increased By ▲ 1.41 (1.8%)
BOP 5.29 Decreased By ▼ -0.05 (-0.94%)
CNERGY 4.36 Increased By ▲ 0.03 (0.69%)
DFML 33.19 Increased By ▲ 2.32 (7.52%)
DGKC 77.80 Decreased By ▼ -0.71 (-0.9%)
FCCL 20.40 Decreased By ▼ -0.18 (-0.87%)
FFBL 31.85 Decreased By ▼ -0.45 (-1.39%)
FFL 10.27 Increased By ▲ 0.05 (0.49%)
GGL 10.33 Increased By ▲ 0.04 (0.39%)
HBL 117.90 Decreased By ▼ -0.60 (-0.51%)
HUBC 135.26 Increased By ▲ 0.16 (0.12%)
HUMNL 6.86 Decreased By ▼ -0.01 (-0.15%)
KEL 4.59 Increased By ▲ 0.42 (10.07%)
KOSM 4.79 Increased By ▲ 0.06 (1.27%)
MLCF 38.26 Decreased By ▼ -0.41 (-1.06%)
OGDC 133.90 Decreased By ▼ -0.95 (-0.7%)
PAEL 23.48 Increased By ▲ 0.08 (0.34%)
PIAA 26.78 Increased By ▲ 0.14 (0.53%)
PIBTL 7.00 Decreased By ▼ -0.02 (-0.28%)
PPL 113.00 Decreased By ▼ -0.45 (-0.4%)
PRL 27.76 Increased By ▲ 0.03 (0.11%)
PTC 14.70 Increased By ▲ 0.10 (0.68%)
SEARL 58.00 Increased By ▲ 1.50 (2.65%)
SNGP 67.34 Increased By ▲ 1.04 (1.57%)
SSGC 11.02 Increased By ▲ 0.08 (0.73%)
TELE 9.24 Increased By ▲ 0.09 (0.98%)
TPLP 11.73 Increased By ▲ 0.06 (0.51%)
TRG 72.80 Increased By ▲ 1.37 (1.92%)
UNITY 24.85 Increased By ▲ 0.34 (1.39%)
WTL 1.41 Increased By ▲ 0.08 (6.02%)
BR100 7,514 Increased By 21.2 (0.28%)
BR30 24,650 Increased By 91.8 (0.37%)
KSE100 72,222 Increased By 170.1 (0.24%)
KSE30 23,801 Decreased By -6.7 (-0.03%)
World

Russia's COVID-19 cases soar; second vaccine due in 2021

  • The vaccine's effectiveness can only be assessed when preliminary or final results of the post-registration trials are released, Vector said.
Published November 20, 2020

MOSCOW: The developers of Russia's second vaccine against COVID-19 on Friday said mass production would begin in 2021, as Russia reported a record daily increase in coronavirus infections.

A recent surge in cases has taken Russia past the 2 million threshold, behind only the United States, India, Brazil and France in total infections.

Authorities have resisted imposing lockdowns across the country as they did earlier this year, however, preferring targeted, regional measures.

Russia last week said its first vaccine against COVID-19, Sputnik V, was 92% effective, according to interim trial results. Around 500,000 doses are due to be produced in November.

Post-registration trials for the second vaccine, EpiVacCorona, being developed by Siberia's Vector institute, are underway.

"Mass production will start in 2021 with the involvement of industrial partners," the institute was cited as saying by news agencies. "To date, 15,000 doses of the vaccine have been issued. By the end of the year 50,000 doses will be released."

Vector's vaccine centre said all volunteers injected with EpiVacCorona had developed antibodies against COVID-19, the Interfax news agency reported without specifying the number of people involved.

The vaccine's effectiveness can only be assessed when preliminary or final results of the post-registration trials are released, Vector said.

Antonina Ploskireva, an epidemiologist at consumer health watchdog Rospotrebnadzor, on Friday urged people to continue observing strict rules for wearing masks and gloves and underlined the importance of social distancing.

"There is a specific trend towards the start of stabilisation as a whole in Russia; however, it is premature to speak about this phase," she was cited as saying by RIA.

Authorities reported 24,318 new coronavirus infections on Friday, including 6,902 in Moscow, bringing the national tally to 2,039,926.

Russia also reported 461 coronavirus-related deaths in the last 24 hours, taking the official death toll to 35,311.

Comments

Comments are closed.